<DOC>
	<DOCNO>NCT00613379</DOCNO>
	<brief_summary>The purpose study : 1 . To assess characterize PK PD PRO 140 administer IV 2 . To assess antiviral activity PRO 140 3 . To assess safety tolerability PRO 140</brief_summary>
	<brief_title>PRO 140 IV Administration Adults With HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<criteria>1 . Males &amp; female , age ≥ 18 year ( minimum adult age determine local regulatory authority ) 2 . Screening plasma HIV1 RNA ≥ 5,000 copies/mL 3 . CD4+ Tlymphocyte cell count ≥ 300 cells/mm3 document count &lt; = 250 cells/mm3 4 . Has take antiretroviral therapy ( ART ) w/in 12 wks Early Screening Visit 5 . Exclusive CCR5tropic virus determine Trofile™ Assay Early Screening Visit 6 . Clinically normal `` clinically significant ( NCS ) '' rest electrocardiogram 7 . Women reproductive potential must negative serum pregnancy test Late Screening Visit &amp; negative urine pregnancy test w/in 72 hr prior first dose study medication , &amp; nonlactating . Male &amp; female subject must agree participate conception process Early Screening Visit Day 59 . 1 . CXCR4 tropic virus dual/mixed tropic ( R5X4 ) virus determine Trofile™ Assay . 2 . Females pregnant , lactate breastfeeding , plan become pregnant study . 3 . History active hepatitis within previous 24 wks 4 . Prior use entry , attachment , CCR5 coreceptor fusion inhibitor , experimental approve .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>treatment naïve</keyword>
</DOC>